A · News · 20260807N
Regulatory Approval Milestones
AGILENT TECHNOLOGIES, INC. · 2026-08-07 · Importance 31 · Surprise 42 · In source text
Agilent received expanded European Union approval for its PD-L1 IHC 22C3 pharmDx test. The CE-marked indication now covers ovarian, fallopian tube, and primary peritoneal carcinoma. This is the test’s eighth CE-marked use in the EU and could increase consumable utilization on existing platforms while supporting adoption of targeted cancer therapies in Europe.
Key facts
- Agilent received expanded EU approval for its PD-L1 IHC 22C3 pharmDx test to cover ovarian, fallopian tube, and primary peritoneal carcinoma. source
- The expanded EU approval is expected to drive increased usage of consumables on existing platforms and supports wider adoption of targeted cancer therapies in Europe. source
- The expanded EU approval for PD-L1 IHC 22C3 pharmDx is the test's eighth CE-marked use in the EU. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | committed | — | Agilent received expanded EU approval for its PD-L1 IHC 22C3 pharmDx test to cover ovarian, fallopian tube, and primary peritoneal… |